Format
Sort by

Send to

Choose Destination

Search results

Items: 17

1.

Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2016 Apr;123(4):865-75. doi: 10.1016/j.ophtha.2015.12.002.

PMID:
26783095
2.

Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2016 Apr;123(4):858-64. doi: 10.1016/j.ophtha.2015.11.030.

PMID:
26778329
3.

Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group..

Ophthalmology. 2016 Mar;123(3):609-16. doi: 10.1016/j.ophtha.2015.10.034.

PMID:
26681392
4.

Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2015 Sep;122(9):1846-53.e5. doi: 10.1016/j.ophtha.2015.05.042.

5.

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group.; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group..

Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020.

6.

Cosmology: Meet the Laniakea supercluster.

Tempel E.

Nature. 2014 Sep 4;513(7516):41-2. doi: 10.1038/513041a. No abstract available.

PMID:
25186896
7.

Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.

Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2014 Oct;121(10):1956-65. doi: 10.1016/j.ophtha.2014.04.020.

8.

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group..

Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. doi: 10.1016/j.ajo.2014.04.004.

9.

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group..

JAMA Ophthalmol. 2014 May;132(5):521-7.

10.

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.01.073.

11.

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group..

Ophthalmology. 2013 Mar;120(3):593-9. doi: 10.1016/j.ophtha.2012.11.037.

12.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group..

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042.

13.

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.

Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053.

14.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

CATT Research Group., Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ.

N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673.

15.
16.

[On the problem of existence of sulfenes. 3. Interception of sulfenes by cyclo-addition to vinylogous carbonic acid amides].

Opitz G, Tempel E.

Justus Liebigs Ann Chem. 1966 Nov;699:68-73. German. No abstract available.

PMID:
6011066
17.

[Enamines. XVI. On the structure of acetylated cyclohexanon-enamine].

Opitz G, Tempel E.

Justus Liebigs Ann Chem. 1966 Nov;699:74-87. German. No abstract available.

PMID:
5986849
Items per page

Supplemental Content

Loading ...
Support Center